TRUMPET A Prospective Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) in the United States

The purpose of this study is to describe patterns of care and disease assessment method, as well as to identify factors influencing physician treatment decisions and settings, referral patterns and CRPC patient characteristics associated with these.
This study will also describe factors influencing treatment decisions including reason(s) for treatment choices and triggers for treatment changes for CRPC as well as describe clinical outcomes based on patient characteristics.

Key Inclusion Criteria:
• Minimum of two rising PSA levels to be measured at least 7 days apart, and serum testosterone level ≤ 1.73 nmol/L (50 ng/dL) or with new evidence of metastatic disease

• Initiating the first active course of anti-cancer treatment for M0 CRPC or for M1 CRPC

• Estimated life expectancy of ≥ 6 months
Peter Jiang, M.D., Ph.D.
Astellas Pharmaceuticals (APUS)
Heather Sights
  • Providence Regional Cancer Partnership - Everett